Table 1.
Commercial CAR T products and their indication and availability worldwide.
| Active substance | Name | Indications | Manufacturer | Approvals | Target | Costimulatory domain |
|---|---|---|---|---|---|---|
| tisagenlecleucel | Kymriah | Pediatric and young adult R/R acute lymphoblastic leukemia; Adult R/R DLBCL; R/R follicular lymphoma | Novartis | FDA, EMA, Health Canada, Swissmedic, Japan’s MHLW, Singapore’s HSA, Australian TGA, UK’s NICE | CD19 | CD137 |
| axicabtagene ciloleucel | Yescarta | R/R large B-cell lymphoma (DLBCL, PMBCL, high grade B-cell lymphoma, DLBCL arising from FL) |
Kite Pharma and Gilead | FDA, EMA, Health Canada, Swissmedic, Japan’s MHLW, China’s NMPA, Australian TGA, UK’s NICE | CD19 | CD28 |
| brexucabtagene autoleucel |
Tecartus | Mantle cell lymphoma; Adult lymphoblastic leukemia | Kite Pharma and Gilead | FDA, EMA, Swissmedic, UK’s NICE, Health Canada | CD19 | CD28 |
| lisocabtagene maraleuecel |
Breyanzi | R/R large B-cell lymphoma | BMS and Juno Therapeutics | FDA, Japan’s MHLW, EMA | CD19 | CD137 |
| idecabtagene vicleucel | Abecma | Multiple myeloma | BMS and Bluebird Bio |
FDA, EMA, Health Canada, Swissmedic, Japan | BCMA | CD137 |
| ciltacabtagene autoleucel | CARVYKTI | Multiple myeloma | Janssen and Johnson & Johnson | FDA | BCMA | CD137 |
| relmacabtagene autoleucel | Carteyva | R/R large B-cell lymphoma | JW Therapeutics | China’s NMPA | CD19 | CD137 |
MHLW, Ministry of Health, Labor and Welfare; HAS, Health Sciences Authority; TGA, Therapeutic Goods Administration; NMPA, National Medical Products Administration; NICE The National Institute for Health and Care Excellence.